NCT05524519Completed
Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder
Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder: a Prospective, Multicentre, Randomized, Controlled Trial
Source: ClinicalTrials.gov · Last updated 22 Aug 2025
Brief summary (registry, in English)
Acupoints are the stimulus points and reactive points for acupuncture to treat diseases. Therefore, this study is designed to detect the pain threshold and temperature of biological specificities of acupoints in healthy control (HC) participants and major depressive disorder (MDD) participants by using pressure pain threshold gauge (PTG) and infrared thermography (IRT). Based on the results of the PTG and IRT tests, the potentially superior acupoints for the treatment of MDD will be selected separately. Then, different acupoint groups selected based on different biological specificities tests will be used for clinical treatment to evaluate the clinical efficacy of intradermal acupuncture (IA) for MDD based on changes in the biological specificities of acupoints.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 160 (actual)
- First submitted
- 30 Aug 2022
- Start date
- 1 Nov 2022
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
- Diseases
- Depression
- NCT number
- NCT05524519
What you commit to
- Study type: Interventional
- Participants enrolled: 160
- From 1 Nov 2022 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with serious primary diseases of cardiovascular diseases, liver diseases, kidney diseases, urinary diseases, and hematological diseases;
- Participants have a mental illness, alcohol dependence, or a history of drug abuse;
- Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape;
- Participants with serious primary diseases of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, neurological disease, and other serious primary diseases, and the disease cannot be effectively controlled clinically;
- MDD caused by organic mental disorders, schizophrenia, bipolar disorder, psychoactive substances, and non-addictive substances;
- Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape;
Other
- Pregnant or lactating participants;
- Participants with intellectual disabilities who cannot cooperate with the questionnaire survey;
- The skin at the test site of participants has scars, hyperpigmentation, red and swollen;
- Participants are participating in other trials.
- Participants with suicidal tendencies;
- Pregnant or lactating participants;
- Participants with intellectual disabilities who cannot cooperate with the questionnaire survey;
- The skin at the test site of participants has scars, hyperpigmentation, red and swollen. IRT is not be performed on female subjects during their menstrual and ovulatory periods;
- Participants are participating in other trials.
Who the study is looking for
- HC who could provide a recent depression screening report, and confirm they have not any cardiovascular, respiratory, digestive, urinary, hematological, endocrine, or neurological disease;
- 18 ≤ age ≤60 years, male or female;
- Participants have clear consciousness and could communicate with others normally;
- Participants could understand the full study protocol and have high adherence. Written informed consent is signed by themselves.
- Patients should meet the diagnostic criteria of the International Classification of Diseases 10th Edition (ICD-10) diagnostic criteria for MDD;
- 18 ≤ age ≤60, male or female;
- Participants have clear consciousness and could communicate with others normally;
- Participants could understand the full study protocol and have high adherence. Written informed consent is signed by themselves.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the Third Affiliated Hospital of Zhejiang Chinese Medical University Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.